{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T09:02:17Z","timestamp":1789981337797,"version":"4.0.1"},"reference-count":75,"publisher":"Informa UK Limited","issue":"12","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2026,8,13]]},"DOI":"10.1080\/14656566.2026.2708165","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:10:41Z","timestamp":1788250241000},"page":"1231-1241","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating the combination of bictegravir and lenacapavir as a single tablet option for HIV"],"prefix":"10.1080","volume":"27","author":[{"given":"Dushyantha T.","family":"Jayaweera","sequence":"first","affiliation":[{"name":"University of Miami Miller School of Medicine","place":["Miami, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"AlBukhari","sequence":"additional","affiliation":[{"name":"University of Miami Miller School of Medicine","place":["Miami, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Pabon","sequence":"additional","affiliation":[{"name":"University of Miami Miller School of Medicine","place":["Miami, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avishka","family":"Jayasekera","sequence":"additional","affiliation":[{"name":"University of Miami Miller School of Medicine","place":["Miami, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunming","family":"Dong","sequence":"additional","affiliation":[{"name":"University of Miami Miller School of Medicine","place":["Miami, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giselle","family":"Galo","sequence":"additional","affiliation":[{"name":"University of Miami Miller School of Medicine","place":["Miami, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoli","family":"Chaudhuri","sequence":"additional","affiliation":[{"name":"University of Miami Miller School of Medicine","place":["Miami, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,9,6]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(24)00212-1"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01381-8"},{"key":"e_1_3_3_4_1","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. U.S. Department of Health and Human Services. JAMA. 2025 [cited 2026 Mar 19]. Available from: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/whats-new"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(23)00151-0"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkae138"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-1010-7"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32299-7"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.24543"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002275"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf135"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33095-7"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab481"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115542"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae423"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407001"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2411858"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae522"},{"key":"e_1_3_3_19_1","unstructured":"Eric Meissner MNR Ruane PJ Sanchez WE et al. Phase III efficacy and safety of switch from B\/F\/TAF to single-tablet BIC\/ LEN in ARTISTRY-2. Conference on Retroviruses and Opportunistic Infections (CROI); 2026 Febraury 22; Abstract # of 513. Dever (CO); 2026."},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(26)00078-0"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61809-7"},{"issue":"1","key":"e_1_3_3_22_1","first-page":"Abstract 270","article-title":"Molecular mechanisms of CD8+ T cell\u2013mediated noncytolytic silencing of HIV-1 transcription","volume":"33","author":"Bendoumou M","year":"2025","unstructured":"Bendoumou M, Nestola DA, Paiardini L, et al. Molecular mechanisms of CD8+ T cell\u2013mediated noncytolytic silencing of HIV-1 transcription. Top Antivir Med. 2025;33(Suppl 1):Abstract 270.","journal-title":"Top Antivir Med"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103985"},{"key":"e_1_3_3_24_1","volume-title":"Conference on Retroviruses and Opportunistic Infections (CROI); 2026 February 22; Abstract 137","author":"Bally Randhawa AI","year":"2026","unstructured":"Bally Randhawa AI, Bekerman E, Lee V. CD4-targeted IL-15 enhanced bNab activity and improved SHIV control after treatment interruption. In: Conference on Retroviruses and Opportunistic Infections (CROI); 2026 February 22; Abstract 137; Denver (CO); 2026."},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1909512"},{"key":"e_1_3_3_26_1","volume-title":"Conference on Retroviruses and Opportunistic Infections (CROI); 2026 Feb 22; Abstract 996","author":"Ema Hughes VJ","year":"2026","unstructured":"Ema Hughes VJ, Yager J, Das M, et al. Once-yearly lenacapavir for PrEP: model-informed dose determination and phase III trial design. Conference on Retroviruses and Opportunistic Infections (CROI); 2026 Feb 22; Abstract 996. Denver (CO); 2026."},{"key":"e_1_3_3_27_1","volume-title":"Conference on Retroviruses and Opportunistic Infections (CROI); 2026 February 22 abstract #15","author":"Cherepanov P","year":"2026","unstructured":"Cherepanov P. Integrase anchors viral RNA to the HIV-1 capsid interior. Conference on Retroviruses and Opportunistic Infections (CROI); 2026 February 22 abstract #15; Denver, Colorado, USA; 2026."},{"key":"e_1_3_3_28_1","volume-title":"Conference on Retroviruses and Opportunistic Infections (CROI); 2026 February 23 Mar. Abstract # 29","author":"Ogbuagu O","year":"2026","unstructured":"Ogbuagu O. Clinical trials and New drugs in the pipeline. In: Conference on Retroviruses and Opportunistic Infections (CROI); 2026 February 23 Mar. Abstract # 29; Denver c(CO); 2026."},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf120"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.7326\/ANNALS-25-01939"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae125"},{"key":"e_1_3_3_32_1","volume-title":"Presented at the 13th IAS Conference on HIV Science; July 13\u201317, 2025; Abstartc# EPO199","author":"Chaudhuri S","year":"2025","unstructured":"Chaudhuri S, Eldib J, Saylor M, et al. Long-acting ART (LEN\/CAB or CAB\/RPV) among viremic persons living with HIV. Presented at the 13th IAS Conference on HIV Science; July 13\u201317, 2025; Abstartc# EPO199; Kigali, Rwanda; 2025."},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5c01625"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2443-1"},{"key":"e_1_3_3_35_1","unstructured":"Pharaceuticals G. Lenacapavir package insert. 2022. Available from: http:\/\/www.fda.gov\/drugsatfda"},{"key":"e_1_3_3_36_1","unstructured":"National Center for Biotechnology Information. PubChem compound summary for CID 133082658 L.R.M. 2026. Available from: http:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Lenacapavir"},{"key":"e_1_3_3_37_1","unstructured":"Pharmaceuticals G. Bictegrevir package insert. 2024. Available from: https:\/\/www.fda.gov\/drugsatfda"},{"key":"e_1_3_3_38_1","unstructured":"National Center for Biotechnology Information. PubChem compound summary for CID 90311989 B.R.M. 2026. 2018. Available from: http:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Bictegravir"},{"key":"e_1_3_3_39_1","unstructured":"Information N.C.f.B. PubChem compound summary for CID 90311989 bictegravir. 2026 [cited 2026 Mar 22]. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Bictegravir"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01474-16"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aea0947"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26125819"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.3c07678"},{"key":"e_1_3_3_44_1","volume-title":"Conference on Retroviruses and Opportunistic Infections (CROI); 2026 February 22; abstract # 205","author":"Matus Nicodemos RA","year":"2026","unstructured":"Matus Nicodemos RA, Ambrozak D, Koup RA, et al. 205 Lenacapavir hyperstabilization of HIV capsid inhibits infection of resting and activated CD4 T cells. Conference on Retroviruses and Opportunistic Infections (CROI); 2026 February 22; abstract # 205; Denver, Colorado, USA; 2026."},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2020.06.003"},{"issue":"4","key":"e_1_3_3_46_1","first-page":"495","article-title":"Pharmacological outlook of Lenacapavir: a novel first-in-class long-acting HIV-1 capsid inhibitor","volume":"31","author":"Di Perri G","year":"2023","unstructured":"Di Perri G. Pharmacological outlook of Lenacapavir: a novel first-in-class long-acting HIV-1 capsid inhibitor. Infez Med. 2023;31(4):495\u2013499.","journal-title":"Infez Med"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3447"},{"key":"e_1_3_3_48_1","unstructured":"Information N.C.f.B. PubChem compound summary for CID 133082658 lenacapavir. 2026 [cited 2026 Mar 22]. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Lenacapavir"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00405-2"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2024.105988"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2023.2169207"},{"issue":"2010","key":"e_1_3_3_52_1","first-page":"262","article-title":"HIV-1 Integrase Strand Transfer Inhibitors","volume":"45","author":"Macor JE","year":"2010","unstructured":"Macor JE. HIV-1 Integrase Strand Transfer Inhibitors. Annu Rep Med Chem. 2010;45(2010):262\u2013276.","journal-title":"Annu Rep Med Chem"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-019-00480-3"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000004372"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf615"},{"key":"e_1_3_3_56_1","volume-title":"Conference on Retroviruses and Opportunistic Infections (CROI); 2026 February 22. Abstract 130","author":"Stephanie Cox KA","year":"2026","unstructured":"Stephanie Cox KA, Hendricks MR, Li J, et al. 130 resistance analyses of the PURPOSE studies through the end of the randomized blinded phase. In: Conference on Retroviruses and Opportunistic Infections (CROI); 2026 February 22. Abstract 130; Denver (CO); 2026."},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(17)30016-4"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000037785"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2024.2415295"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz999"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07091-1"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad500.1416"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(23)00327-2"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003783"},{"key":"e_1_3_3_65_1","volume-title":"Presented at: 13th IAS Conference on HIV Science; July 2025. Abstract OAC0505","author":"Bekker L-G","year":"2025","unstructured":"Bekker L-G, Moodley D, Harkoo I, et al. Inclusion of pregnant and lactating people in the PURPOSE 1 study: efficacy, safety, and pharmacokinetics. In: Presented at: 13th IAS Conference on HIV Science; July 2025. Abstract OAC0505; Kigali, Rwanda; 2025."},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(26)00112-8"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000713"},{"key":"e_1_3_3_68_1","unstructured":"Liverpool UO. HIV drug interactions. Editor: liverpool HIV interactions. 2026. URL https:\/\/www.hiv-druginteractions.org\/"},{"key":"e_1_3_3_69_1","volume-title":"Conference on Retroviruses and Opportunistic Infections (CROI); 2021 March 6,10 abstract # 89","author":"Rebecca Begley JL","year":"2021","unstructured":"Rebecca Begley JL, Dvory-Sobol H, West S, et al. The clinical evaluation of drug interactions with oral lenacapavir and probe drugs. Conference on Retroviruses and Opportunistic Infections (CROI); 2021 March 6,10 abstract # 89; 2021."},{"key":"e_1_3_3_70_1","unstructured":"Services. P.o.A.G.f.A.a.A.G.f.t.U.o.A.A.i.A.a.A.w.H.D.o.H.a.H. Drug interactions capsid inhibitor adult and adolescent. 2024. Available from: https:\/\/clinicalinfo.hiv.gov\/en"},{"key":"e_1_3_3_71_1","unstructured":"Agency. E.M. Biktarvy (bictegravir\/emtricitabine\/tenofovir alafenamide): CHMP assessment report (EMA\/293559\/2018). 2018 [cited 2026 Mar 25h]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/biktarvy-epar-public-assessment-report_en.pdf"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30149-3"},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00133-22"},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(26)00307-7"},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(26)00033-0"},{"key":"e_1_3_3_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01948-8"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2026.2708165","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14656566.2026.2708165","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2026.2708165","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T08:11:47Z","timestamp":1789978307000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2026.2708165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":75,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,8,13]]}},"alternative-id":["10.1080\/14656566.2026.2708165"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2026.2708165","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-04-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}